Early Parkinson's signs in Morocco: a key challenge for diagnosis

Parkinson's disease in Morocco is a progressive neurodegenerative condition caused by the loss of dopamine-producing neurons. While classic symptoms like tremors and muscle rigidity appear late, earlier subtle signs include loss of smell, sleep disturbances, persistent fatigue, constipation, and mood changes. Diagnosis in Morocco is often delayed until motor symptoms are advanced, and access to specialized care is uneven, particularly outside major urban centers, due to a limited number of specialists and treatment costs. A notable characteristic in Morocco is the high frequency of genetic forms of the disease, often appearing earlier and affecting multiple family members. North Africa, especially Morocco, shows a high prevalence of the "LRRK2 G2019S" genetic mutation, which is significant globally for Parkinson's. This genetic specificity offers a scientific opportunity to understand disease mechanisms and develop targeted treatments. Diagnosis remains complex as it relies on clinical examination, and early, non-specific signs can be mistaken for other conditions or normal aging. The absence of a simple, reliable biological test contributes to late diagnoses. Current research on biological, genetic, and imaging biomarkers, such as alpha-synuclein and specific genetic mutations, is promising for earlier and more precise diagnosis, leading to personalized medicine. Current treatments primarily aim to compensate for dopamine deficiency, with L-DOPA being the standard, but they